This company is a spin-out company from the Royal Veterinary College. It is focused on therapeutic vaccines for treating viral diseases of economic importance. The company in alliance with European partners is developing a platform technology for the delivery of DNA vaccines using controlled release drug technology. Targeted diseases include hepatitis B, hepatitis C and HIV.